Stock Pulse
Abbott Laboratories (ABT) is expected to announce Q1 2025 earnings on April 16th, with projected EPS of $1.07 (+9.2% year-over-year) and revenue of $10.42 billion (+4.5% year-over-year) [1], [4], [6], [10]. Analysts have raised their EPS estimates, and the company has a Zacks Rank #2 (Buy), suggesting potential market outperformance [1], [6]. Growth is anticipated across most divisions, particularly Medical Devices, driven by Diabetes Care and Structural Heart [1], [4]. However, increased competition from Dexcom's newly approved diabetes device poses a potential risk to Abbott's market share in this segment [5]. While institutional investors recently decreased their holdings, the longer-term outlook remains positive [7]. Despite a recent 2% stock decline, likely influenced by the competitive threat [5], [6], Abbott has a history of exceeding earnings expectations [10] and is considered a resilient investment [2].